Bristol-Myers Squibb Co (BMY) Stake Increased by Tokio Marine Asset Management Co. Ltd.

Share on StockTwits

Tokio Marine Asset Management Co. Ltd. lifted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,615 shares of the biopharmaceutical company’s stock after acquiring an additional 494 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Bristol-Myers Squibb were worth $344,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BMY. Vanguard Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares during the period. Vanguard Group Inc lifted its stake in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares during the period. BlackRock Inc. lifted its stake in shares of Bristol-Myers Squibb by 2.4% during the third quarter. BlackRock Inc. now owns 114,573,885 shares of the biopharmaceutical company’s stock worth $7,112,747,000 after buying an additional 2,660,326 shares during the period. Dodge & Cox lifted its stake in shares of Bristol-Myers Squibb by 0.8% during the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after buying an additional 264,100 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Bristol-Myers Squibb by 23.4% during the third quarter. Jennison Associates LLC now owns 21,526,559 shares of the biopharmaceutical company’s stock worth $1,336,369,000 after buying an additional 4,080,245 shares during the period. 73.35% of the stock is owned by hedge funds and other institutional investors.

Shares of BMY stock traded down $1.08 on Thursday, reaching $49.89. 31,494,553 shares of the company were exchanged, compared to its average volume of 20,495,434. The stock has a market capitalization of $82.25 billion, a P/E ratio of 12.54, a P/E/G ratio of 2.22 and a beta of 0.81. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $67.44. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The firm had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. Bristol-Myers Squibb’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.68 earnings per share. On average, analysts expect that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.29%. Bristol-Myers Squibb’s payout ratio is 41.21%.

BMY has been the subject of several research reports. BMO Capital Markets reiterated a “buy” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Thursday, January 3rd. Bank of America set a $53.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Friday, January 25th. ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday, January 4th. Morgan Stanley set a $54.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. Finally, Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $59.40.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Stake Increased by Tokio Marine Asset Management Co. Ltd.” was posted by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.fairfieldcurrent.com/news/2019/03/14/tokio-marine-asset-management-co-ltd-has-344000-stake-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.